B. Braun Medical Inc. (US)’s Post

#AUA24 - Data from Phase 2b SunRISe-1 exploration demonstrates remarkable outcomes of TAR-200 monotherapy, achieving over 80% complete remission in patients grappling with HR-NMI #bladdercancer https://lnkd.in/gVAbcd_d #news #media #BREAKING #pharma #pharmaceutical #Science #TeleMedicine #medicine #digitalhealth #PersonalizedMedicine #Europe #patientcare #healthcare #MedComms #MedicalAffairs #Medical #PatientSafety

New HMA case study: Patient Journey Analysis for a New Oncology Drug. Bundled payment can serve as a disincentive to provide high-cost drugs, so the client was interested in pursuing reimbursement policy options that would ensure appropriate reimbursement to these facilities, thus ensuring patient access to the drug during the treatment regimen. Read the final results and the HMA approach: https://bit.ly/3zpcAn1

Pharmacy Practice in Focus: Oncology Launches Peer-Review Process: "Pharmacy Practice in Focus: Oncology" welcomes the launch of the peer-review process. #finance #pharmacy #lifesciences

Study Shows Cost-Effectiveness of Serplulimab in Treating Metastatic Squamous NSCLC in China Combining serplulimab with chemotherapy for first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) is a cost-effective strategy, according to a study from a Chinese perspective. The study used a survival model and found that the addition of serplulimab increased quality-adjusted life years (QALYs) at an incremental cost that was below the threshold in China. The sensitivity analysis highlighted progression-free survival (PFS) as the most influential factor. Strategic pricing agreements and adoption of the combination therapy could lead to revised guidelines and insurance coverage adjustments. The study provides a foundation for integrating serplulimab into standard care practices for metastatic squamous NSCLC in China. For more details please click the link! https://lnkd.in/dXwc-bJA #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

🚨 A new targeted drug combination treatment, described as a ‘step-change in care’ for #cancer patients, has today been recommended by NICE - National Institute for Health and Care Excellence. ✅ Dabrafenib, marketed as Finlee, in combination with trametinib, which is sold as Spexotras, (both made by Novartis) is being recommended in final draft guidance for treating BRAF V600E mutation-positive glioma. 📈 Clinical trials show the new treatment stalls the tumour growth in people for an average of more than two years – three times longer than current drugs. 🗣️ Read on to find out NHS England perspective 👉  https://lnkd.in/ePuUJAh3 #pharma #lifesciences #braincancer #clinicaltrial

Are the brands focusing on the right areas when providing adherence support to their patients? According to PURE Engagement, Physicians consider the drugs’ side effects to be the main reason for patients to discontinue a drug where financial burden is ranked #3. To find out what other factors physicans contribute to drug drop off or to learn more, see: https://lnkd.in/edZbfiUE #Oncology #Pharma #Adherence #PURE

💪 Novartis has had a strong start to 2024 with net sales of $11.8Bn ( 10%) and net income increasing to $2.68Bn ( 25%) compared to Q1 2023. Here is my financial breakdown: 📈 Key growth drivers included the cardiovascular drug Entresto ( 34%), psoriasis medication Cosentyx ( 23%), MS drug Kesimpta ( 66%), breast cancer drug Kisqali ( 51%), and radioconjugate Pluvicto ( 47%). 📉However, this growth was partially offset by increased generic competition for Lucentis (-25%) and Gilenya (-25%). #Novartis #q1 #financials #visualisation #data #breakdown #pharma #basel

Vividion Therapeutics, Inc. Initiates P-I Trial of VVD-130850 for Treating Advanced Solid and Hematologic Tumors #vividiontherapeutics #vvd130850 #solidtumors #hematologictumors #clinicaltrial #phase1 #safety #efficacy #tolerability #pharmacokinetics #pharmacodynamics #patients

Obe-cel, an investigational therapy utilizing CD19 CAR T cells, aims to address the limitations in clinical effectiveness and safety observed with existing CD19 CAR T cell treatments. Autolus Therapeutics presents extended follow-up results and further data analysis from the key Phase Ib/II FELIX study of obecabtagene autoleucel (obe-cel) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Benefit from Expert Insights and Extensive Analysis with DelveInsight Business Research LLP's ASCO 2024 Exclusive Coverage! https://lnkd.in/gE3gUFyM #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

A review of 129 cancer therapeutics granted accelerated approval between 2013 and 2023 showed that, to date, fewer than half (20/46, 43%) demonstrated a clinical benefit in confirmatory trials. Time to withdrawal decreased from 9.9 years to 3.6 years, and time to regular approval increased from 1.6 years to 3.6 years. Trends seem to be moving in the right direction, balancing earliest possible access against raising undue patient expectations of benefit. Certainly helps explain FDA's new found insistence on having confirmatory trials up and recruiting before accelerated approval is granted. https://lnkd.in/dmbGduj3